- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02092194
High Versus Standard Volume Hemodiafiltration in Asia
Effectiveness of High-volume Online Hemodiafiltration Compared to Standard Volume Online Hemodiafiltration. A Prospective, Multicenter, Randomized, Open-labelled Interventional Study.
Online hemodiafiltration (HDF) may improve clinical outcome in end-stage renal disease. The supported mechanism is the improved clearance of uremic toxins by convective transporter. However, It has not been elucidated which convection volume is optimal, especially in Asia. A total of 60 participants receiving conventional hemodialysis will be randomly assigned to receive either high dose convective volume (33-43 L/treatment) post-dilution online HDF or standard dose (16.8-21.5 L/treatment) for 24 weeks. The primary outcome is the change of serum β2 microglobulin levels between baseline and after 24 weeks. The secondary outcomes will include changes in the nutritional markers, inflammatory markers, and blood pressure from baseline to after treatment.
This would be the first multicenter prospective, randomized controlled trial to determine whether large convective volume improves the treatment efficacy in Korean patients undergoing post-dilution online HDF.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sung Gyun Kim, MD
- Phone Number: +82-10-3586-8561
- Email: imnksk@gmail.com
Study Contact Backup
- Name: Soo Jin Kim, MD
- Phone Number: +82-10-8722-8078
- Email: dongangagy@lycos.co.kr
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Contact:
- Kwon Wook Joo, MD
- Email: junephro@snu.ac.kr
-
Principal Investigator:
- Kwon Wook Joo, MD
-
Seoul, Korea, Republic of
- Yonsei University Gangnam Severance Hospital
-
Contact:
- Hyeong Cheon Park, MD
- Email: amp97@yuhs.ac
-
Principal Investigator:
- Hyeong Cheon Park, MD
-
Seoul, Korea, Republic of
- Chung-ang University Hospital
-
Contact:
- Su-Hyun Kim, MD
- Email: sh76so@cau.ac.kr
-
Principal Investigator:
- Su-Hyun Kim, MD
-
Seoul, Korea, Republic of
- Korea University Anam Hospital
-
Contact:
- Won-Yong Cho, MD
- Email: wonyong@korea.ac.kr
-
Principal Investigator:
- Won-Yong Cho, MD
-
Seoul, Korea, Republic of
- Shamyook Medical Center
-
Contact:
- Sun Ryoung Choi, MD
- Email: ryounge@hanmail.net
-
Principal Investigator:
- Sun-Ryoung Choi, MD
-
-
Gyeonggi-do
-
Anyang, Gyeonggi-do, Korea, Republic of
- Hallym University Sacred Heart Hospital
-
Contact:
- Soo Jin Kim, MD
- Phone Number: +82-10-8722-8078
- Email: dongangagy@lycos.co.kr
-
Contact:
- Sung Gyun Kim, MD
- Phone Number: +82-31-380-3976
- Email: imnksk@gmail.com
-
Principal Investigator:
- Sung Gyun Kim, MD
-
Sub-Investigator:
- Soo Jin Kim, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients on thrice-weekly standard hemodialysis for > 3 months
- Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
- Patients willing to provide written informed consent.
Exclusion Criteria:
- Patients with active infectious or uncontrolled inflammatory disorders
- Patients with any uncontrolled malignant disease
- Patients with recent major cardiovascular disease during the last 6 months
- Patients who are likely to receive kidney transplant within the following 1 year
- Patients whose life expectancy < 12 months
- Patients considered by investigator to have difficulty in participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Dose online HDF
Proposed target convection volume; 16.8-21.5
L/treatment (70-90 mL/min)
|
convection volume; 16.8-21.5
L/treatment (70-90 mL/min)
Other Names:
|
Experimental: High Dose online HDF
Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
|
Convection volume; 33-43 L/treatment (140-180 mL/min)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
changes in the serum concentration of β2 microglobulin
Time Frame: between baseline and 24 weeks after treatment
|
between baseline and 24 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dialysis Adequacy
Time Frame: 24 weeks
|
Kt/V by the single pool variable volume formula.
|
24 weeks
|
Inflammatory markers
Time Frame: 24 weeks
|
C-reactive protein (CRP), interleukin-6, tumor necrosis factor-α.
|
24 weeks
|
Nutritional status
Time Frame: 24 weeks
|
normalized protein nitrogen appearance rate, serum albumin, serum protein, subjective global assessment (SGA)
|
24 weeks
|
Intradialytic hypotension
Time Frame: 24 weeks
|
Number of episode of symptomatic hypotension
|
24 weeks
|
Quality of Life
Time Frame: baseline and 24 weeks after treatment
|
SF-36-K (Korean version)
|
baseline and 24 weeks after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Won-Yong Cho, MD, Korea University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KHSG-201301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Standard Dose Online HDF
-
Western Galilee Hospital-NahariyaCompleted
-
Bangkok Metropolitan Administration Medical College...CompletedEnd Stage Renal DiseaseThailand
-
Pontifícia Universidade Católica do ParanáFresenius AGCompletedChronic Kidney DiseaseBrazil
-
EXcorLab GmbHCompletedEnd-stage Renal DiseaseGermany
-
Temple UniversityCancer Support Community, Research and Training Institute, PhiladelphiaCompletedBreast NeoplasmsUnited States
-
Sodra Alvsborgs HospitalCompletedHearing ImpairmentSweden
-
Ohio State University Comprehensive Cancer CenterRecruitingColorectal CarcinomaUnited States
-
Arizona State UniversityNational Institutes of Health (NIH); National Center for Complementary and...Completed
-
McMaster UniversityNot yet recruitingPost Concussion Syndrome